期刊
EPILEPSY & BEHAVIOR
卷 9, 期 3, 页码 457-463出版社
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.yebeh.2006.04.021
关键词
oxcarbazepine; partial seizures; quality of life; QOLIE-31
Objective. Quality of life (QOL) was assessed in patients who switched to oxcarbazepine monotherapy because of the lack of efficacy or poor tolerability of their current antiepileptic drug (AED). Method. This open-label, single-arm study consisted of patients aged >= 12 years with partial onset seizures. Oxcarbazepine (8-10 mg/kg/day for children, 600 mg/day for adults) was titrated up over 4 weeks while the existing AID was tapered off. QOL was evaluated at baseline and end of study (Week 16) using the validated-in-epilepsy QOLIE-31 questionnaire. Results. For all patients who completed the QOLIE-31 at baseline and completion, a statistically significant improvement was noted for both the composite and multi-item subscale QOL scores (P < 0.05 vs baseline). Statistically significant mean percentage improvements of >= 10% from baseline (range = 10.8-50.1%) were also noted. Significant improvements were seen in health-related QOL for patients who experienced seizure freedom or >= 50% reductions in seizure frequency with oxcarbazepine monotherapy. Conclusions. Patients with partial seizures who switched to oxcarbazepine monotherapy showed statistically significant, clinically relevant improvements in QOL. (c) 2006 Published by Elsevier Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据